BELLUS Health Receives Nasdaq Deficiency Notice Relating to Market Value

Thursday, October 16, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces that it received a Nasdaq Staff Deficiency Letter dated October 10, 2008, stating that, for 10 consecutive trading days, the market value of the Company's listed securities has been below the minimum $50 million requirement for continued inclusion on The Nasdaq's Global Market under Marketplace Rule 4450(b)(1)(A). The Company believes that the recent decline in its market value is due to the general pressure on equity markets worldwide.

In accordance with Marketplace Rule 4450(e)(4), the Company has 30 calendar days, or until November 10, 2008, to regain compliance to which BELLUS Health will strive towards. If the market value of the Company's common stock is US$50,000,000 or more for a minimum of 10 consecutive business days at any time prior to November 10, 2008, Nasdaq may determine that the Company has regained compliance with the applicable listing requirements. If compliance with the Rules cannot be demonstrated by November 10, 2008, Nasdaq will provide written notification that the Company's securities will be delisted, at which time the Company may appeal the determination to a Listing Qualifications Panel.

Among other alternatives the Company is considering if it cannot regain compliance with the requirements of The Nasdaq's Global Market as set forth above, is applying to transfer its securities to The Nasdaq Capital Market. Currently, the Company believes that it meets the criteria to transfer to The Nasdaq Capital Market. However, there can be no assurance that Nasdaq will approve the Company's transfer application.

The Company's common stock is also listed on the Toronto Stock Exchange (TSX) and such listing is not affected by the notice received from Nasdaq.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store